Skip to content
Search

Latest Stories

EXCLUSIVE: Why pharmacy needs collective leadership

By Professor Mahendra Patel 

As a member of the UK Commission on Pharmacy Professional Leadership, and deputy chair of the Leadership, Policy and Professionalism Working Group, I’ve found it to be an infectiously fascinating and truly worthwhile programme of work.


I’ve been meaning to share some of my personal views and thoughts for some time around the Commission and its work, and especially now that the report is now public.

I’d be dismissive of the truth if I didn’t acknowledge the declining interest and the clear disengagement of colleagues with our professional leadership body. Worryingly, this has become even more apparent in recent times than in previous years. Being a founding member and ardent supporter of the Royal Pharmaceutical Society (RPS), it’s naturally upsetting to take in.

I’ve been a devoted and committed national board member of the RPS for many years, as well as a member of the assembly and Treasurer. As a consequence, I feel I’m relatively well versed around understanding the workings of the RPS. Through this privileged insight I’m proud to shout out and loudly, that absolutely yes, the RPS has done so much amazing work over the years, and continues to do so – benefiting so many and across different sectors and age groups.

However, as we all know in general there will always be room for improvement, but in the case of our professional leadership body perhaps this could even mean radical improvement in some instances requiring changes to governance.

  • We need to identify and encourage leaders with a high skill-set, clear pedigree and gravitas, and who are passionate and selfless about taking the profession forward, to come to the helm more. They should themselves have a proven track record of successful leadership roles within their own organisations.
  • We must not rely solely upon an election system in choosing our leaders, nor on one whose primary entry criteria is membership of the professional body. Election results are clearly not representative of the membership with regularly much less than 10 per cent of members voting – in the opinion of many driven by popularity rather than substance. My litmus test as a minimum standard for anyone standing as a national board member, let alone standing for any office-bearing positions, is to gauge how successful they may be if they were, for example, applying for a senior non-executive position at, for example, a hospital trust, corporate organisation, charitable organisation, or equivalent in other settings. I must confess that when I started as an RPS board member I would have failed and dare I say quite miserably.
  • We need to build a cultural change in mindset — believing that pharmacy actually means pharmacists and pharmacy technicians, who have in many ways and for too long been ignored.

So it’s welcoming, and perhaps not even surprising, to see the Chief Pharmaceutical Officers (CPhOs) from all four devolved nations coming together to commission the work on pharmacy professional leadership during perceivably the most important times in the history of the NHS – when all resources and capacity have been challenged to the fullest and beyond.

Frankly, when we first started the Commission work I genuinely didn’t believe that we’d ever get to conclude the work within the timeframe and at the pace it did, and the depth and breadth that it covered. Also, to emphasise, that it was as representative as practically possible under the circumstances, with vast amounts of evidence gathered through the numerous webinars, discussions and debates across the four nations and from all corners of pharmacy, including those on the ground – where it really matters. I believe pharmacy has over 150 organisations, which depicts the scale of the task in hand.

Additionally, growing this wealth of evidence has been so well supported by the depth of knowledge and experience shared by all the members of the five working groups, and coming together as a whole Commission at various points in an open and collaborative manner. The driving force came from the relentless efforts of the two independent chairs. They synergistically and seemingly effortlessly combined in bringing their own individual expertise and knowledge as leaders to the forefront. I saw them as being wholly independent throughout the process! Something to learn from for many perhaps, and not least myself!

The Commission’s recommendations are certainly exciting and realistic; refreshing and rejuvenating—appealing and inviting – inclusive and collaborative, all with a view to bringing huge opportunities for the devoted to be able to influence at the highest levels for the right reasons and the right causes.

As a seasoned academic and building on a highly successful community pharmacy background, I’m delighted to see that science, education, research, and practice can all come together on one platform, and having an equal and authoritative voice for pharmacy. Furthermore, the Commission report recognises the opportunities in building on the amazing international reputation of our professional body, one that I’ve personally witnessed whilst actively promoting the RPS and its resources when working with countries such as Lebanon, Morocco, India, Portugal, China, and the USA. It also made me appreciate more how much value the royal status itself carries internationally. We must truly capitalise on these opportunities.

In terms of where we are now, we need to drive the professions forward with passion and commitment, embrace change, and take advantage of the new and emerging roles in pharmacy, for the betterment of patient care not just for today but also for the future, and not just nationally but also internationally. Moreover, we must closely align with all the devolved nations through their own aims and objectives on a seamless basis.

The next steps of the Commission’s recommendations, from what I’ve seen and heard to date, are creating encouraging interest from various corners of the professions and age groups. The independent appointment of the transitional, advisory Pharmacy Leadership Council Chair by the CPhOs and, following on from this, its members is certainly something to watch out for, as is the duty to collaborate in ensuring one cohesive voice. I still think there should be some role for the current independent chairs during the transition –

What a waste it would be to lose that excellent resource. Separate to that, I personally would like to see some big gun from the medical profession (or equivalent) leading the Council – what a coup that would be in terms of how our leadership body would be perceived externally and be better accepted by the medical profession and not just by our own.

It seems we are yet to be informed about any of the details beyond the CPhOs saying they are developing options and will work collaboratively on the next steps. I’m confident that there will be transparency throughout these steps, which is crucial for respect and trust to be maintained – something that appears to be fading when it comes to our current professional leadership body.

So to restore confidence and to revive interest and excitement amongst all our pharmacy colleagues, it’s vital we come together through the federated model and work together in harmony, in an authoritative, collaborative, and inclusive manner.

I agree it’s a gigantic task in bringing everything to fruition in good time, and not least in securing the funding to support and implement the recommendations. I await with interest the twists and turns this may bring! However, it is ultimately us as the profession that will be steering the direction of travel forward and not, as some may think, the CPhOs – I think they’ve enough on as it is!!

The important thing is enabling the collaboration amongst pharmacy leadership bodies – so we have credible and authoritative leadership that is effective and speaks with one voice to Government, regulators, patients and employers. The recommendation to establish a Council is key to achieving this. The Council can then help to empower the professional bodies to shape and lead the future for our professions.

This is a one-time opportunity wherever it eventually leads to, perhaps even a royal college, who knows? So let’s do all we can to make it work for the better, wherever we take it to, and together. It’s all in our hands!

Professor Mahendra G Patel OBE is deputy chair, Leadership, Policy and Professional Working Group, UK Commission on Pharmacy Professional Leadership.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less